RecruitingNCT04792801

PET TDM FDG-Choline as a Decision-making Tool for Routine Care on the Liver Transplant List for HCC

Evaluation of PET TDM FDG-Choline as a Decision-making Tool for Routine Care on Inclusion on the Liver Transplant List for Hepatocellular Carcinoma


Sponsor

University Hospital, Lille

Enrollment

100 participants

Start Date

Jun 22, 2021

Study Type

OBSERVATIONAL

Conditions

Summary

HCC is the most common malignant liver tumor for which liver transplantation is one of the pivotal curative treatments. The best possible selection of patients who are candidates for transplantation is essential in the current context of a shortage of transplants. Performing a PET CT scan is not currently recommended in the pre-liver transplant workup for HCC. However, PET CT using in a complementary manner the FDG and Choline tracers appears promising in the management of HCC in view of its wide use in oncology and its major diagnostic and prognostic contribution compared to conventional imaging. In order to address this issue, a prospective cohort study including patients from the University Hospital of Rouen and Lille with hepatocellular carcinoma meeting the criteria for indication of liver transplantation validated in SPC will be set up, the main objective of which will be to assess the decision-making contribution of PET TDM FDG and Choline in addition to conventional imaging in the pre-transplant assessment.


Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This study is evaluating whether a combination of FDG-PET and choline PET scans (two types of whole-body imaging) can help doctors make better decisions about liver transplant eligibility for patients with hepatocellular carcinoma (HCC), the most common form of liver cancer. The goal is to better identify patients most likely to benefit from transplantation. **You may be eligible if...** - You are a liver transplant candidate with hepatocellular carcinoma (HCC) at the University Hospitals of Lille or Rouen - Your transplant plan has been approved by a multidisciplinary team - Your AFP score (a cancer marker score) is 2 or below - Your HCC diagnosis is confirmed by imaging or biopsy - You are affiliated with social security **You may NOT be eligible if...** - Your AFP score is above the required threshold - You are not currently on the liver transplant waiting list - Your HCC does not meet the imaging or staging criteria Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

RADIATIONPET TDM FDG-Choline

Performing an FDG TDM PET and a Choline TDM PET at two different times


Locations(1)

Hop Claude Huriez Chu Lille

Lille, France

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT04792801


Related Trials